Ralph Schiess was appointed as Chief Science Officer at Onconetix, Inc..
“On December 15, 2023, Onconetix appointed Ralph Schiess, 45, as Chief Science Officer of Onconetix, effective immediately”
Onconetix, Inc. — fact timeline
Source-grounded facts extracted from Onconetix, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christian Brühlmann was appointed as Chief Strategy Officer at Onconetix, Inc..
“On December 15, 2023, Onconetix appointed Christian Brühlmann, 47, as Chief Strategy Officer of Onconetix, effective immediately”
Jon Garfield resigned as Chief Financial Officer at Onconetix, Inc..
“Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.”
Neil Campbell was appointed as President and Chief Executive Officer at Onconetix, Inc..
“appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors”
Onconetix, Inc. amended Amendment to Asset Purchase Agreement with Veru Inc. with Veru Inc. valued at Amendment of $4 million installment payment to $1 million cash plus issuance of 3,000 shares of Seri (effective 2023-09-29).
“On September 29, 2023, the Company entered into an Amendment (the "Amendment") of the Asset Purchase Agreement (the "Purchase Agreement"), dated as of April 19, 2023, by and between the Company and Veru Inc., a Wisconsin corporation ("Veru") relating to the sale of the product ENTADFI TM .”
Onconetix, Inc. entered into Exclusive Distribution Agreement with Cardinal Health 105, LLC valued at Three-year term, one-time start-up fee of $15,500, monthly account management fee of $7,000 (effective 2023-09-20).
“On September 21, 2023, Blue Water Biotech, Inc. (the "Company") entered into an Exclusive Distribution Agreement (the "Exclusive Distribution Agreement"), effective as of September 20, 2023 (the "Effective Date"), with Cardinal Health 105, LLC ("Cardinal Health").”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 18, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “ Company ”), received a written notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “ Minimum Bid Requirement ”) as the bid price of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), had closed below $1.00 per share for 30 cons”
Vuk Jeremić resigned as Member of the Board of Directors at Onconetix, Inc..
“Effective as of September 2, 2023, Vuk Jeremić resigned as a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”) as well as from his positions as a member of the Compensation Committee and Nominating and Corporate Governance Committee of the Board.”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“August 22, 2023, Blue Water Biotech, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its quarterly report on Form 10-Q for the quarter ended June 30, 2023 (the “ 10-Q ”). Consistent with the Listing Rules, the Company has 60 calendar days from the date of the Notice to provide Nasdaq with a specific plan to achieve and sustain compliance with”
Jon Garfield was appointed as Chief Financial Officer and interim principal executive officer at Onconetix, Inc..
“Effective August 16, 2023, Board has appointed Jon Garfield, the Company’s Chief Financial Officer, to serve as the Company’s interim principal executive officer during the pendency of Mr. Sapirstein’s appointment.”
James Sapirstein was appointed as Interim Executive Chairman at Onconetix, Inc..
“the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023.”
Joseph Hernandez resigned as Chairman, Chief Executive Officer, and Member of the Board of Directors at Onconetix, Inc..
“Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”).”
Onconetix, Inc. entered into Inducement Letter with a certain holder of existing preferred investment options valued at approximately $2,709,973 (effective 2023-07-31).
“On July 31, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into a common stock preferred investment options exercise inducement offer letter (the “Inducement Letter”) with a certain holder (the “Holder”) of existing preferred investment options (“PIOs”) to purchase shares of the Company’s common stock”
Onconetix, Inc. engaged EisnerAmper LLP as its auditor.
“On July 6, 2023, the Audit Committee appointed EisnerAmper LLP (“EA”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and related interim periods.”
Mayer Hoffman McCann P.C. resigned as auditor of Onconetix, Inc..
“On June 29, 2023, Mayer Hoffman McCann P.C. (“MHM”), Blue Water Biotech, Inc.’s (the “Company”) independent registered public accounting firm, informed the Company that it resigned, effective June 29, 2023.”
Onconetix, Inc. entered into Purchase Agreement with WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC (effective 2023-06-13).
“On June 13, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with WraSer, LLC, a Mississippi limited liability company, Xspire Pharma, LLC, a Mississippi limited liability company (collectively, the “Seller”), and Legacy-Xspire Holdings, LLC, a Delaware limited liability company and the parent company of the Seller (“Parent”).”
Onconetix, Inc.: Amended bylaws to reduce stockholder meeting quorum requirement from a majority to one-third of voting power (effective 2023-05-31).
“On May 31, 2023, the Board amended the Company’s bylaws to reduce the quorum requirement at meetings of the Company’s stockholders from a majority of the voting power of the outstanding shares of stock of the Company entitled to vote, to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote, effective immediately.”
Onconetix, Inc. shareholders approved Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
“Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm Appointment by the Company’s audit committee of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 9,717,035 248,537 5,889 -”
Onconetix, Inc. shareholders approved Amendment to the Amended and Restated 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares at the 2023-05-31 meeting.
“Proposal No. 2 – Amendment to 2022 Equity Incentive Plan The amendment to the 2022 Plan to (i) increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares was approved. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 6,191,117 659,202 14,138 3,107,004”
Onconetix, Inc. shareholders approved Election of Mr. James Sapirstein as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified at the 2023-05-31 meeting.
“Proposal No. 1 – Election of Directors Mr. James Sapirstein was elected as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote James Sapirstein 6,207,510 656,947 3,107,004”
Onconetix, Inc.: Amended bylaws to reflect corporate name change to Blue Water Biotech, Inc (effective 2023-04-21).
“In connection with the name change, the Company amended the Company’s bylaws to reflect the corporate name Blue Water Biotech, Inc., also effective on April 21, 2023. No other changes were made to the bylaws.”
Onconetix, Inc.: Amended Second Amended and Restated Certificate of Incorporation to change corporate name from 'Blue Water Vaccines Inc.' to 'Blue Water Biotech, Inc.' (effective 2023-04-21).
“On April 21, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), filed an amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from “Blue Water Vaccines Inc.” to “Blue Water Biotech, Inc.” (the “Name Change Amendment”). The name change was effective as of April 21, 2023.”
Onconetix, Inc. completed an acquisition involving Veru Inc. for $100,000,000 (closed 2023-04-19).
“of the Transaction The Company purchased substantially all of the Seller’s assets, rights and property related to the ENTADFI TM Business for a total possible consideration of $100,000,000 (as described below). The ENTADFI TM Business capitalizes on the demonstrable success of the FDA-approved drug ENTADFI TM for treating benign prostatic hyperplasia and”
Onconetix, Inc. entered into Purchase Agreement with Veru Inc. valued at total possible consideration of $100,000,000 (effective 2023-04-19).
“On April 19, 2023, Blue Water Vaccines Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the "Purchase Agreement") with Veru Inc., a Wisconsin corporation (the "Seller").”
Onconetix, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $3,900,000 (effective 2023-03-29).
“On March 29, 2023, Blue Water Vaccines Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Agent”), to create an at-the-market equity program under which it may sell up to $3,900,000 of shares of the Company’s common stock (the “Shares”) from time to time through the Agent (the “ATM Offering”).”
Tim Ramdeen was appointed as Director at Onconetix, Inc..
“Effective as of January 13, 2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.”
Kimberly Murphy resigned as Director at Onconetix, Inc..
“Effective as of January 13, 2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”), as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of the Compensation Committee and Audit Committee of the Board.”
Vuk Jeremić was appointed as Director at Onconetix, Inc..
“Effective as of November 4, 2022, the Board appointed Vuk Jeremić to serve as a member of the Board and a member of the Nominating and Corporate Governance Committee of the Board and Compensation Committee of the Board.”
Michael Venerable resigned as Director at Onconetix, Inc..
“Effective as of November 4, 2022, Michael Venerable resigned as a member of the Board of Directors (the "Board") of Blue Water Vaccines Inc. (the "Company").”
James Sapirstein was appointed as member of the Board at Onconetix, Inc..
“Effective as of February 23, 2022, the Board appointed James Sapirstein to serve as a member of the Board.”
John Rice resigned as member of the Board of Directors at Onconetix, Inc..
“Effective as of February 23, 2022, John Rice resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc.”
James Sapirstein was appointed as member of the Board at Onconetix, Inc..
“Effective as of February 23, 2022, the Board appointed James Sapirstein to serve as a member of the Board.”
John Rice resigned as member of the Board of Directors at Onconetix, Inc..
“Effective as of February 23, 2022, John Rice resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.